The company initiated two new oncology studies in October and November and said a first-line zipalertinib NDA submission is expected to complete in November.
The company disclosed Fast Track designation for its lead EGFR inhibitor and set an end-of-phase-1 FDA meeting for later in 2026, alongside cash from its August IPO.
The company presented updated Phase 1/2 SOLARA trial data at the IASLC 2026 World Conference on Lung Cancer, following recent FDA Fast Track designation for the drug.